Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tonabersat in the Prophylaxis of Migraine With Aura

This study has been completed.
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
Minster Research Ltd
ClinicalTrials.gov Identifier:
NCT00332007
First received: May 30, 2006
Last updated: August 28, 2009
Last verified: August 2009

May 30, 2006
August 28, 2009
May 2006
August 2008   (final data collection date for primary outcome measure)
  • Difference in the mean number of aura attacks experienced between treatment groups [ Time Frame: 12 week treatment period ] [ Designated as safety issue: No ]
  • Difference in the mean number of migraine headache days between treatment groups [ Time Frame: 12 week treatment period ] [ Designated as safety issue: No ]
  • Incidence of adverse events [ Time Frame: 12 week treatment period ] [ Designated as safety issue: Yes ]
  • Difference in the mean number of aura attacks experienced between treatment groups
  • Difference in the mean number of migraine headache days between treatment groups
  • Incidence of adverse events
Complete list of historical versions of study NCT00332007 on ClinicalTrials.gov Archive Site
  • Mean number of headache days in each treatment period. [ Time Frame: 12 week treatment period ] [ Designated as safety issue: No ]
  • Mean number of auras followed by headache in each treatment period. [ Time Frame: 12 week treatment period ] [ Designated as safety issue: No ]
  • Mean number of headache days in each month of treatment in each treatment period. [ Time Frame: Mean monthly ] [ Designated as safety issue: No ]
  • Mean number of auras and/or migraine headache during each treatment period. [ Time Frame: 12 week treatment period ] [ Designated as safety issue: No ]
  • Mean number of migraine headache attacks in each treatment period. [ Time Frame: 12 week treatment period ] [ Designated as safety issue: No ]
  • Speed of effect of treatment. [ Time Frame: First month for which difference between treatments identified ] [ Designated as safety issue: No ]
  • Mean monthly consumption of rescue medication. [ Time Frame: Mean monthly ] [ Designated as safety issue: No ]
  • Mean duration of auras in each treatment period. [ Time Frame: Mean over 12 week treatment period ] [ Designated as safety issue: No ]
  • Mean number of symptoms associated with auras in each treatment period. [ Time Frame: 12 week treatment period ] [ Designated as safety issue: No ]
  • Mean number of headache days in each treatment period.
  • Mean number of auras followed by headache in each treatment period.
  • Mean number of headache days in each month of treatment in each treatment period.
  • Mean number of auras and/or migraine headache during each treatment period.
  • Mean number of migraine headache attacks in each treatment period.
  • Speed of effect of treatment.
  • Mean monthly consumption of rescue medication.
  • Mean duration of auras in each treatment period.
  • Mean number of symptoms associated with auras in each treatment period.
  • Number of patients defined as a responder
Not Provided
Not Provided
 
Tonabersat in the Prophylaxis of Migraine With Aura
A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura

Overall trial objectives:

  1. Can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura
  2. How well tolerated is treatment with tonabersat

The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of aura and migraine headache and so be effective as prophylactic treatment

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Migraine With Aura
  • Drug: Tonabersat
    two tablets once daily
  • Drug: Placebo
    two tablets once daily
  • Experimental: 1
    Tonabersat 40 mg daily
    Intervention: Drug: Tonabersat
  • Placebo Comparator: 2
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
39
August 2008
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with an established history of migraine of at least one year meeting the diagnostic criteria of the International Classification of Headache Disorders - Edition 2 (Appendix 2) and who experience at least one aura a month.
  • Male or female patients between 18-65 years of age
  • Women of child bearing potential must be using a reliable form of contraception (defined in the protocol) for at least 3 months prior to enrolment and they must have a negative pregnancy test at screening with no intention of becoming pregnant during the study period

Exclusion Criteria:

  • Patients experiencing headache other than migraine or tension headache
  • Overuse of acute migraine treatments defined as more than 14 daily doses per month with analgesics or more than 9 daily doses per month of ergots or triptans within the last two months
  • Migraine prophylactic treatment within two months prior to entry to the trial
  • Patients taking any of the following medications for migraine: beta-blockers, tricyclic antidepressants (during the last 2 months), antiepileptic dugs (during the last 2 months), calcium channel blockers, monoamine oxidase inhibitors, daily NSAIDs, daily paracetamol, high dose magnesium supplements (600mg/day). Parenteral administration of botulinum toxin is also excluded. These drugs are permitted when given for diseases other than migraine provided that, in the opinion of the investigator the dose can be kept constant throughout the trial.
  • Patients who, in the opinion of the investigator, have significant cerebrovascular disease e.g. transient ischaemic attacks, stroke
  • Patients who, in the opinion of the investigator, have clinically significant cardiovascular disease
  • Patients suffering from a current clinical diagnosis of a major depressive disorder or schizophrenia
  • Patients with renal dysfunction , defined as a serum creatinine of greater than 125% of the upper limit of normal for their age group
  • Patients with hepatic dysfunction defined as a liver function test (AST, ALT, alkaline phosphatase, bilirubin) of greater than twice the upper limit of normal for their age group
  • Patients with known alcohol or other substance abuse
  • Use of an investigational drug (for any indication) within 30 days or 5 half-lives, whichever is the longer, prior to screening
  • Women who are pregnant or breast feeding
  • Women of childbearing potential not using a reliable form of contraception
  • Patients with any other clinically significant condition which, in the investigators opinion, would render them unsuitable for this study
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00332007
TON/02/05-CLIN
No
Professor J Olesen, University of Copenhagen
Minster Research Ltd
University of Copenhagen
Principal Investigator: Jes Olesen, MD University of Copenhagen, Department of Neurology, Glostrup Hospital
Minster Research Ltd
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP